Lopinavir
[대역어] 로피나비르
[용어속성] Drug
[용어속성] Drug
Efficacy of canakinumab in mild or severe COVID‐19 pneumonia
경증 또는 중증 COVID-19 폐렴에서 카나키누맙의 효능
Comparative Study
[키워드] absence
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
administration
Beta
canakinumab
cause
caused
collected
collected data
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID‐19
enrolled
Hospitalized
Human monoclonal antibody
ICU
IL1‐β
IMPROVE
Inflammation
intensive care
laboratory parameter
Laboratory parameters
Lopinavir
Lopinavir/ritonavir
lopinavir/ritonavir)
Mild
monoclonal antibody
oxygen
oxygen flow
oxygen support
Oxygenation
P/F ratio
pandemic
Patient
patients treated
Pneumonia
rapid increase
reduced
reduction in
reported
respiratory
Respiratory function
Result
Ritonavir
Safety
SARS CoV2
SARS‐CoV‐2
SARS‐CoV‐2 infection
severe acute respiratory syndrome Coronavirus
severe adverse events
single dose
Standard therapy
supply
therapeutic option
therapeutic strategy
therapy
treat
[DOI] 10.1002/iid3.400 PMC 바로가기 [Article Type] Comparative Study
[DOI] 10.1002/iid3.400 PMC 바로가기 [Article Type] Comparative Study
Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered A single-center, retrospective, observational study
중국 동북부 7개 도시에서 완전히 회복된 COVID-19 환자 55명에 대한 의료 치료 단일 센터, 후향적, 관찰 연구
Observational Study
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
Administered
administration
Antibiotics
antiviral drug
antiviral drugs
antiviral therapy
benefit
caused
China
Clinical outcome
clinical outcomes
Co-infection
collected
Controlled trial
controlled trials
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
demographics
double-blind
drug
early administration
effective
emerging disease
glucocorticoid
Glucocorticoids
immunomodulators
Intervention
Laboratory
Linezolid
Lopinavir
Lopinavir/ritonavir
lopinavir/ritonavir)
median
medical treatment
medication
Mild
mild symptoms
moxifloxacin
observational study
Patient
patients with COVID-19
reduce
respiratory
retrospective
risk
Ritonavir
SARS-CoV-2
Seven
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
severe group
severe symptoms
single-center
Symptoms
the disease
transferred
treat
treated
Treatment
umifenovir
[DOI] 10.1097/MD.0000000000023923 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1097/MD.0000000000023923 PMC 바로가기 [Article Type] Observational Study
Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs
누락된 임상 시험 데이터: 잠재적인 COVID-19 약물에 대한 기본 데이터의 증거 격차
Research
[키워드] adverse events
blinded
caution
checked
Clinical findings
clinical trial
Clinical trial transparency
clinical trials
ClinicalTrials
Concordance
conducted
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 treatment
disease
dosages
drug
Evidence
Favipiravir
Google Scholar
Hydroxychloroquine
Identifier
identify
in vitro
include
information
lack
Lopinavir
missing
morbidity and mortality
pandemic
Potential treatment
potential treatments
regimen
registry
Repurposed drugs
Result
Safety information
searched
Sponsor
synthesis
Treatment
Trial
trials
[DOI] 10.1186/s13063-021-05024-y PMC 바로가기 [Article Type] Research
[DOI] 10.1186/s13063-021-05024-y PMC 바로가기 [Article Type] Research
Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial
글루코코르티코이드(CORTIVID)를 사용한 COVID-19 폐렴의 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] absolute difference
active cancer
Admission
age
allergy
ambient
approved
arterial blood
Barcelona
baseline
biochemical
Blinding
Block randomisation
block size
Blood
Breastfeeding
C-reactive protein
C-reactive protein (CRP
candidate
clinical
Clinical outcome
clinical outcomes
clinical trial
contraindication
Control
control group
Controlled trial
COVID-19
COVID-19 admission
COVID-19 pneumonia
criteria
death
decrease
defined
detect
Deterioration
Device
diabete
Diabetes Mellitus
diagnosis of SARS-CoV-2
discretion
dissemination
drug
drug treatment
early treatment
Effectiveness
element
elevated
eligible
emergency room
ethics committee
EudraCT
exclusion criteria
expected
explained
ferritin
Follow-up
followed by
following
glucocorticoid
Glucocorticoids
groups
hospital
Hospital admission
hypertension
ICU
Identifier
IL-6
immunosuppressants
IMPROVE
inclusion criteria
independent
Infection
inflammatory biomarkers
Informed consent
intensive care
intensive care unit
interleukin
interleukin-6
Intervention
intervention group
intravenous
intravenous infusion
Laboratory
Loading dose
Lopinavir
Lopinavir/ritonavir
maintenance dose
management
manic
manic disorder
mechanical ventilation
Medical devices
Medicine
Medicines
Methylprednisolone
Nasopharyngeal swab
nasopharyngeal swabs
number
objective
outcome
outcome assessor
outcome assessors
Outpatient
oxygen
oxygen saturation
PaO
parallel-group
partial pressure
Partial pressure of oxygen
participant
Patient
patient age
patients
patients with COVID-19
Pharmacy
Placebo
Pneumonia
polymerase chain
Potential
Pregnancy
primary endpoint
Primary outcome
procalcitonin
proportion
protocol
Psychiatric
Psychological
psychotic
pulse
Pulses
Quadruple blind
radiological
random
randomisation
randomised
randomised controlled trial
randomizeR
receive
recommendation
recruit
recruitment
Registered
Remdesivir
required
researcher
reverse transcriptase
Reverse transcriptase polymerase chain reaction
Ritonavir
RT-PCR
Sample size
SARS-CoV-2
SARS-CoV-2 pneumonia
sequence
Spain
Spanish
sputum
Standard of care
status
stratified
study outcomes
Study protocol
supplementary material
Symptom
Tablet
the patient
therapy
title
total sample size
transcriptase
Treatment
treatment failure
Trial
Trial registration
two group
two groups
two-tailed
type I
type II error
uncontrolled hypertension
unit
university
Version
website
with COVID-19
[DOI] 10.1186/s13063-020-04999-4 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04999-4 PMC 바로가기 [Article Type] Letter
Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial
COVID-19(COVID-AT)로 인한 급성 호흡 곤란 증후군 환자에서 동종 간엽 기질 세포의 효능을 평가하기 위한 이중 맹검, 무작위, 대조 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
24 hours
7-point ordinal scale
acute respiratory distress
acute respiratory distress syndrome
Administered
administration
Admission
Adult patient
Adult patients
Adverse
Adverse drug reactions
AEs
age
All trial participants
all-cause mortality
allergy
Allogeneic
ARDS
assessment
assigned
baseline
Biomarker
blinded
Blinding
C-reactive protein
carcinoma
carcinoma in situ
carried
cellular
chain
change
childbearing potential
Chloroquine
Clinical practice
clinical status
clinical trial
coagulation test
coagulation tests
conducted
Control
control arm
Course
COVID
COVID-19
CRF
criteria
CT scan
cumulative incidence
current
Cytokines
D-dimer
Day
death
described
determined by
Diagnosis
disease
dissemination
double-blind
drug
Duration
ECMO
Efficacy
Efficacy and safety
element
eligible
End
endpoints
enrolment
EudraCT
evaluate
evaluate the effect
event
exclusion criteria
Extracorporeal
extracorporeal membrane oxygenation
failure
ferritin
fibrosis
FiO2
form
GRADE
grade 3
greater
Haemodialysis
handling
hemofiltration
history
hospital
Hospitalization
hydroxy
ICU
ICU admission
IMPROVE
include
inclusion criteria
Informed consent
intravenous
Intravenous administration
intravenous dose
intubation
Invasive mechanical ventilation
invasive ventilation
investigational medicinal product
involved
laboratory confirmation
laboratory-confirmed SARS-CoV-2 infection
lactation
LDH
less
Level
Local
Lopinavir
Lopinavir/ritonavir
lung disorder
lymphocyte
marker
Mechanical
mechanical ventilation
Medicine
Medicines
Mesenchymal stromal cells
moderate to severe
Mortality
MSC
negative pregnancy test
neoplasm
neutrophil
neutrophil counts
Non-invasive
number
objective
occur
off-label
opinion
Ordinal Scale
organ
oropharyngeal swab
oropharyngeal swabs
Other
outcome
oxygen
oxygen saturation
Oxygen therapy
PaO2
PaO2/FiO2 ratio
parameters
participant
Patient
PCR
percentage
Placebo
polymerase chain reaction
Pregnancy
primary endpoint
product
Production
profile
progression
protocol
Pulmonary embolism
pulmonary fibrosis
Pulmonary function tests
randomised
randomised controlled trial
randomization
Randomized
Randomly
Rapid antigen tests
reaction
receive
recruitment
Registered
Remdesivir
report
respiratory
Respiratory distress syndrome
Resuscitation
Ritonavir
SAEs
Sample size
SARS-COV-2 infection
secondary
Secondary endpoints
Sequential Organ Failure Assessment
Serious Adverse Events
SOFA
Spain
specificity
specimen
Sponsor
Standard of care
status
stromal cell
stromal cells
Study protocol
subpopulations
supplemental oxygen
supplementary material
syndrome
the cell
the disease
the patient
the primary endpoint
the WHO
time
Tocilizumab
Tolerability
Treatment
treatment arm
treatment for COVID-19
treatment group
Treatment protocol
Trial
trial participant
Trial registration
unit
website
women
worldwide pandemic
written consent
[DOI] 10.1186/s13063-020-04964-1 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04964-1 PMC 바로가기 [Article Type] Letter
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study
바리시티닙은 SARS-CoV-2 폐렴에 대한 코르티코스테로이드 치료 환자의 호흡 기능을 개선합니다: 관찰 코호트 연구
Observational Study
[키워드] adjusted
arterial oxygen partial pressure
Baricitinib
block viral entry
Combination
Corticosteroid
Corticosteroids
COVID-19
cytokine
Cytokine storm
discharge
end point
enrolled
European
FiO2
greater
HCQ
High-dose
Hospitalization
IMPROVE
inhibitor
Jak
Janus kinase
Lopinavir
Lopinavir/ritonavir
moderate
moderate to severe
network
Observational cohort study
observational study
oxygen
oxygen partial pressure
oxygen saturation
PaO2
partial pressure
Patient
patients treated
patients with moderate
patients with SARS-CoV-2
pharmacoepidemiology
pharmacovigilance
pneumocyte
Pneumocytes
Pneumonia
Prevent
primary end point
proportion
Pulmonary function
pulse oximetry
reduction
required
requiring supplemental oxygen
Respiratory function
risk
Ritonavir
SARS-CoV-2
SARS-CoV-2 pneumonia
secondary
severe SARS-CoV-2
SpO2
SpO2/FiO2
Statistics
supplemental oxygen
Viral
viral entry
Weighting
[DOI] 10.1093/rheumatology/keaa587 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1093/rheumatology/keaa587 PMC 바로가기 [Article Type] Observational Study
The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial
경증 및 중등도 COVID-19 환자에서 이버멕틴의 효능 및 안전성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
ACE inhibitor
ACE inhibitors
acute respiratory syndrome
Adverse drug reaction
Adverse drug reactions
AIDS
allergy
anticipated
Anticoagulant
Anticoagulants
Asthma
Bandar Abbas
Blinding
Breastfeeding
Captopril
chest X-ray
clinical
clinical symptom
Clinical symptoms
clinical trial
clinical trials
company
Computed tomography
Confirmed
Control
control group
control groups
Controlled trial
COVID-19
COVID-19 symptom
criteria
Critical
CXR
Department
discharge
Diseases
dissemination
dose
Drug allergy
education
Efficacy and safety
element
evaluate
exclusion criteria
FIVE
France
group
groups
history
Hospital stay
Hospitalization
Hospitalization Mechanical ventilation
hydroxychloroquine sulfate
ICU admission
incidence
include
inclusion criteria
India
Infection
Informed consent
Inpatients
Interferon beta-1a
intervention group
Iran
Ivermectin
Kidney disease
liver
loiasis
Lopinavir
Lopinavir/ritonavir
mechanical ventilation
Mild
mild COVID-19 symptom
mild COVID-19 symptoms
mild pneumonia
Ministry of Health
moderate
Moderate COVID-19
moderately severe COVID-19
MSD
number
objective
Open-label
Other
outcome
Outpatient
outpatients
parallel-group
participant
Patient
patients
patients with moderate
PCR
pharmaceutical
Pharmaceutical Company
Phase 3
Pneumonia
Pregnancy
Primary outcome
Primary outcomes
protocol
random
randomization
Randomized
Randomized controlled trial
receive
regimen
Registered
registration date
registration number
registry
respiratory
Ritonavir
routine care
Sample size
secondary outcome
selected
Seven
Severe acute respiratory syndrome
single dose
single-center
standard treatment
status
Study protocol
subsequent
supplementary material
table
the patient
Treatment
treatment group
Trial registration
twice a day
two group
two groups
underlying diseases
Version
Warfarin
website
weight
[DOI] 10.1186/s13063-020-04988-7 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04988-7 PMC 바로가기 [Article Type] Letter
Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial
중증 COVID-19 사례 관리에 대한 정맥 면역글로불린(IVIg)의 효과 평가: 무작위 대조 시험
Randomized Controlled Trial
[키워드] Admission
both groups
Combination
control group
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
demographic data
dose
Effect
Evaluating
Factors
group
hospital
Hospital admission
Hospital stay
Hydroxychloroquine
ICU
Immunoglobulin
Infection
intensive care unit
intervention group
Intravenous immunoglobulin
IVIG
Lopinavir
Lopinavir/ritonavir
management
mechanical ventilation
Mortality
mortality rate
no significant difference
P-value
pandemic
Patient
positive
positive relationship
Previous studies
previous study
pulmonary
Pulmonary infection
Pulmonary infection.
Randomized controlled trial
reducing
Ritonavir
severe cases
severe COVID-19
significantly lower
Support
supportive care
survivor
Treatment
two group
two groups
Viral
Viral load
were recorded
[DOI] 10.1016/j.intimp.2020.107205 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1016/j.intimp.2020.107205 PMC 바로가기 [Article Type] Randomized Controlled Trial
Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial
Original Article
[키워드] Admission
Adverse reaction
analyzed
assigned
Atazanavir
clinical
Clinical outcome
clinical recovery
clinical trial
Coronavirus disease 2019
COVID-19
discharged
double-blind
Efficacy
Efficacy and safety
enrolled
Frequency
groups
HCQ
Hospital stay
Hydroxychloroquine
ICU
ICU admission
intensive care
Intervention
Intubated
intubation
Lopinavir
Lopinavir/ritonavir
median
moderate
Mortality
nausea
participant
patients
Primary outcome
Randomized
Randomly
receive
reduced
reported
Safety
Secondary outcomes
single dose
statistically
vomiting
[DOI] 10.22037/ijpr.2021.115157.15243 PMC 바로가기 [Article Type] Original Article
[DOI] 10.22037/ijpr.2021.115157.15243 PMC 바로가기 [Article Type] Original Article